Search
Amrubicin
go.drugbank.com/drugs/DB06263InvestigationalAmrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sa...
Lactose
go.drugbank.com/drugs/DB04465ApprovedInvestigationalWithdrawnA disaccharide of glucose and galactose in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.
Mixtures: SYNTHROID® 112 MCG TABLETASDaprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigationalDaprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK. Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent in...
Synonyms: Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-Futibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigationalFutibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival. FGFR was investigated in ...
Tifcemalimab
go.drugbank.com/drugs/DB18914Investigationalunder investigation in clinical trial NCT06095583 (Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC
Rosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalRecent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele.
Synonyms: (±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione, (RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedionProducts: Avandia 2mg, Avandia 4mgNirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationaldrug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase 3 DeFi trial, where a confirmed objective response rate was observed to be
Sevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigationalSevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. Sevaber...
Odanacatib
go.drugbank.com/drugs/DB06670InvestigationalOdanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].